Extensive human cytomegalovirus (HCMV) genomic DNA in the renal tubular epithelium early after renal transplantation: Relationship with HCMV DNAemia and long-term graft function

Journal of Medical Virology

Volumn 82, Issue 1, 2010, Pages 85-93

  Li, Ying Ting ^a   Emery, Vincent C ^a   Surah, Saloni ^a   Jarmulowicz, Michael ^a   Sweny, Paul ^a   Kidd, I Michael ^a   Griffiths, Paul D ^a   Clark, Duncan A ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

CMV disease; Humoral; In situ; Infection; Rejection

Indexed keywords

CASPASE 3; COMPLEMENT COMPONENT C4D; CREATININE; GENOMIC DNA;

ACUTE GRAFT REJECTION; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DNA HYBRIDIZATION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; HUMORAL IMMUNITY; IN SITU HYBRIDIZATION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE EPITHELIUM;

BIOPSY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; EPITHELIUM; GENOME, VIRAL; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES;

HUMAN HERPESVIRUS 5;

EID: 74849121787     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21662     Document Type: Article

References (42)

1. Andoniou CE, gli-Esposti MA. 2006. Insights into the mechanisms of CMV-mediated interference with cellular apoptosis. Immunol Cell Biol 84:99-106.
2. Bohmig GA, Exner M, Watschinger B, Wenter C, Wahrmann M, Osterreicher C, Saemann MD, Mersich N, Horl WH, Zlabinger GJ, Regele H. 2001. C4d deposits in renal allografts are associated with inferior graft outcome. Transplant Proc 33:1151-1152.
3. Boyce NW, Hayes K, Gee D, Holdsworth SR, Thomson NM, Scott D, Atkins RC. 1988. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy. Transplantation 45:706-709.
4. Chiou SH, Liu JH, HsuWM, Chen SS, Chang SY, Juan LJ, Lin JC, Yang YT,WongWW, LiuCY, LinYS, LiuWT,WuCW. 2001.Up-regulation of Fas ligand expression by human cytomegalovirus immediate-early gene product 2: A novel mechanism in cytomegalovirus-induced apoptosis in human retina. J Immunol 167:4098-4103.
5. Clark DA, Ait-Khaled M, Wheeler AC, Kidd IM, McLaughlin JE, Johnson MA, Griffiths PD, Emery VC. 1996. Quantification of human herpesvirus 6 in immunocompetent persons and postmortem tissues from AIDS patients by PCR. J Gen Virol 77:2271-2275.
6. Darlington J, Super M, Patel K, Grundy JE, Griffiths PD, Emery VC. 1991. Use of the polymerase chain reaction to analyse sequence variation within a major neutralizing epitope of glycoprotein B (gp58) in clinical isolates of human cytomegalovirus. J Gen Virol 72:1985-1989.
7. DesJardin JA, Gibbons L, Cho E, Supran SE, Falagas ME, Werner BG, Snydman DR. 1998. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 178:1783-1786.
8. Dickenmann MJ, CathomasG, Steiger J, Mihatsch MJ, ThielG,Tamm M. 2001. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 71:764-767.
9. Dukers DF, Oudejans JJ, Vos W, ten Berge RL, Meijer CJ. 2002. Apoptosis in B-cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method. J Pathol 196:307-315.
10. Einsele H, Ehninger G,HebartH,Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Loffler J, Wagner S,Muller CA. 1995. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86:2815-2820.
11. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. 1999. The dynamics of human cytomegalovirus replication in vivo. J ExpMed 190:177-182.
12. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. 2000. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355:2032-2036.
13. Fahim T,Bohmig GA, ExnerM, Huttary N, KerschnerH,Kandutsch S, Kerjaschki D, Brambock A, Nagy-Bojarszky K, Regele H. 2007. The cellular lesion of humoral rejection: Predominant recruitment of monocytes to peritubular and glomerular capillaries. Am J Transplant 7:385-393.
14. Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, Sgarabotto D, Torre-Cisneros J, Uknis ME. 2007. Cytomegalovirus in transplantation-Challenging the status quo. Clin Transplant 21:149-158.
15. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA. 1997. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in livertransplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350:1729-1733.
16. Gerna G, Lilleri D, Fornara C, Comolli G, Lozza L, Campana C, Pellegrini C, Meloni F, Rampino T. 2006. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 6:2356-2364.
17. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. 1989. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261:3561-3566.
18. Griffiths PD, Ait-Khaled M, Bearcroft CP, Clark DA, Quaglia A, Davies SE, Burroughs AK, RollesK, Kidd IM, Knight SN, Noibi SM, Cope AV, Phillips AN, Emery VC. 1999. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus. JMed Virol 59:496-501.
19. Helantera I, Koskinen P, Finne P, Loginov R, Kyllonen L, Salmela K, Gronhagen-Riska C, Lautenschlager I. 2006. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 19:893-900.
20. Holma K, Tornroth T, Gronhagen-Riska C, Lautenschlager I. 2000. Expression of the cytomegalovirus genome in kidney allografts during active and latent infection. Transpl Int 13:S363-S365.
21. Humar A, Siegal D, Moussa G, Kumar D. 2005. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 192: 1154-1157.
22. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC. 2006. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6:2134-2143.
23. Kidd IM, Clark DA, Ait-Khaled M, Griffiths PD, Emery VC. 1996. Measurement of human herpesvirus 7 load in peripheral blood and saliva of healthy subjects by quantitative polymerase chain reaction. J Infect Dis 174:396-401.
24. Kidd IM,ClarkDA, Sabin CA, Andrew D, Hassan-Walker AF, Sweny P, Griffiths PD, Emery VC. 2000. Prospective study of human betaherpesviruses after renal transplantation: Association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 69:2400-2404.
25. Kloover JS, Soots AP, Krogerus LA, Kauppinen HO, Loginov RJ, Holma KL, Bruggeman CA, Ahonen PJ, Lautenschlager IT. 2000. Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1 vascular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft. Transplantation 69:2641-2647.
26. Liapis H, Storch GA, Hill DA, Rueda J, Brennan DC. 2003. CMV infection of the renal allograft is much more common than the pathology indicates: A retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. Nephrol Dial Transplant 18:397-402.
27. Lilley BN, Ploegh HL. 2005. Viral modulation of antigen presentation: Manipulation of cellular targets in the ER and beyond. Immunol Rev 207:126-144.
28. Ljungman P, Griffiths P, Paya C. 2002. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34:1094-1097.
29. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC. 1999. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 340:1462-1470.
30. Martelius T, Krogerus L, Hockerstedt K, Bruggeman C, Lautenschlager I. 1998. Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts. Hepatology 27:996-1002.
31. Martelius TJ, Blok MJ, Inkinen KA, Loginov RJ, Hockerstedt KA, Bruggeman CA, Lautenschlager IT. 2001. Cytomegalovirus infection, viral DNA, and immediate early-1 gene expression in rejecting rat liver allografts. Transplantation 71:1257-1261.
32. Mattes FM, Hainsworth EG, Geretti AM, Nebbia G, Prentice G, Potter M, Burroughs AK, Sweny P, Hassan-Walker AF, Okwuadi S, Sabin C, AmootyG, Brown VS, Grace SC, Emery VC, Griffiths PD. 2004.A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 189:1355-1361.
33. Mocarski ES, Jr. 2004. Immune escape and exploitation strategies of cytomegaloviruses: Impact on and imitation of the major histocompatibility system. Cell Microbiol 6:707-717.
34. Opelz G, Dohler B, Ruhenstroth A. 2004. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 4:928-936.
35. Osman HK, Peiris JS, Taylor CE, Warwicker P, Jarrett RF, Madeley CR. 1996. "Cytomegalovirus disease" in renal allograft recipients: Is human herpesvirus 7 a co-factor for disease progression? J Med Virol 48:295-301.
36. Paya C, Humar A, Dominguez E,Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD, Valganciclovir Solid Organ Transplant Study Group. 2004. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.AmJ Transplant 4:611-620.
37. Plachter B, Nordin M, Wirgart BZ, Mach M, Stein H, Grillner L, Jahn G. 1992. The DNA-binding protein P52 of human cytomegalovirus reacts with monoclonal antibody CCH2 and associates with the nuclear membrane at late times after infection. Virus Res 3:265-276.
38. Ratnamohan VM, Chapman J, Howse H, Bovington K, Robertson P, Byth K, Allen R, Cunningham AL. 1998. Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. Transplantation 66:877-882.
39. Regoes RR, Bowen EF, Cope AV, Gor D, Hassan-Walker AF, Prentice HG, Johnson MA, Sweny P, Burroughs AK, Griffiths PD, Bonhoeffer S, Emery VC. 2006. Modelling cytomegalovirus replication patterns in the human host: Factors important for pathogenesis. Proc Biol Sci 273:1961-1967.
40. Ricart MJ, Malaise J, Moreno A, Crespo M, Fernandez-Cruz L. 2005. Cytomegalovirus: Occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 20:ii25-ii32, ii62.
41. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. 1991. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 324:1005-1011.
42. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, Stinson EB, Brown BW, Jr., Merigan TC, Schroeder JS. 1999. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study. Circulation 100:61-66.